Physician profile
John F Redding
NPI 1215978739
$7,567.94
in general payments reported to CMS, 2019-2025
64 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $1,338 · 2021: $1,138 · 2022: $1,245 · 2023: $1,439 · 2024: $1,036 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,647.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $939.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $932.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $796.51 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $637.61 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.67 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $358.58 | 2019-2024 | Shingrix, Trelegy Ellipta |
| Pfizer INC. | $272.50 | 2019-2024 | |
| Amgen INC. | $258.98 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $244.02 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $206.27 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $200.28 | 2019-2021 | |
| Astellas Pharma US INC | $188.75 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $184.39 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.88 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $88.14 | 2019-2023 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Redding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.